Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Formycon AG (FYB.DE)

XETRA - XETRA Delayed Price. Currency in EUR
87.10+0.40 (+0.46%)
At close: 05:36PM CET
Advertisement

Formycon AG

Fraunhoferstrasse 15
Martinsried
Planegg 82152
Germany
49 89 864 667 100
https://www.formycon.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees146

Key Executives

NameTitlePayExercisedYear Born
Dr. Stefan GlombitzaCEO, COO & Member of Exec. BoardN/AN/A1965
Dr. Friedrich-Wilhelm SteinwegCo-FounderN/AN/AN/A
Dr. Nicolas Combe Ph.D.Co-Founder & CFON/AN/AN/A
Dr. Andreas SeidlChief Scientific Officer & Member of Exec. BoardN/AN/A1970
Ms. Nicola MikulcikChief Bus. Officer & Member of Exec. BoardN/AN/A1971
Sabrina MullerSr. Mang. of Corp. Communications & Investor RelationsN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Formycon AG develops and markets biosimilar products. Its product pipeline includes FYB201, a biosimilar candidate for Lucentis, an ophthalmic drug used in the treatment of neovascular age-related macular degeneration and other serious eye diseases; FYB202, a biosimilar candidate for Stelara, a biopharmaceutical used in the treatment of inflammatory diseases, such as moderate to severe psoriasis, as well as for the treatment of Crohn's disease and ulcerative colitis, which is in the Phase III clinical trial; and FYB203, a biosimilar candidate for Eylea to treat neovascular age-related macular degeneration and other eye diseases that is in Phase III clinical trials. The company is also developing FYB206; and FYB207, an antiviral drug for the treatment of COVID-19. It has a collaboration agreement with Leukocare AG to develop stable formulations for various candidates in its product pipeline. The company was formerly known as Nanohale AG and changed its name to Formycon AG in 2012. Formycon AG was founded in 1999 and is headquartered in Planegg, Germany.

Corporate Governance

Formycon AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement